According to Alcimed, a research group based in France, as many as 20% of small biotechnology firms in Europe could go bankrupt this year. These firms need new funding within the next year and a half in order to survive. Alcimed estimates that the sector needs at least $2.6 billion in annual funding to maintain current operations.

Source: Reuters